Company Overview
| Stock Name | Henlius |
|---|---|
| Stock Code | 02696 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家中國領先的生物製藥公司,旨在為全球患者提供質高價優的創新藥物。主要專注研發單克隆抗體藥物並提供相關技術服務,已商業化推出生物類似藥產品HLX01(漢利康),並自主開發20種以上候選生物藥及多種腫瘤免疫聯合療法。 |
| Listing Date | 2019-09-25 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市徐匯區虹梅路1801號凱科國際大廈A座9樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.henlius.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 49.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 100 shares |
| Entry Threshold | To be extracted |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2019-09-12 to 2019-09-17 |
| Global Offering Shares | 64,695,400 shares |
| HK Public Offer Shares (Initial) | 6,469,600 shares (10.0%) |
| Public Offer Lots (Initial) | 64,696lots (Pool A32,348lots,Pool B32,348lots) |
| International Placing Shares (Initial) | 58,225,800 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 539,128,704 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 34.2% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 3,208,891,840 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 3,020 lots | 302,048 | HK$ 14,981,581 |
| 4,704 lots | 470,404 | HK$ 23,332,038 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 21.29B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 亏损约人民币504.8百万元 |
| Period-End Cash Balance | 人民币959.0百万元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | 约人民币43亿元 |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2017 | 2018 | 2019-03 |
|---|---|---|---|
| Revenue | 33,910 | 7,421 | 924 |
| Cost of sales | -15,019 | -5,398 | |
| Gross profit | 18,891 | 2,023 | 924 |
| Other income and gains, net | 1,165 | 30,308 | 4,830 |
| Selling and distribution expenses | -5,082 | ||
| Administrative expenses | -87,334 | -109,050 | -32,339 |
| Net finance costs | -55,159 | -57,896 | -8,955 |
| Profit before tax | -379,997 | -500,220 | -158,123 |
| Income tax expense | -4,330 | -4,569 | |
| Profit for the year | -384,327 | -504,789 | -158,123 |
| Profit attributable to owners | -270,562 | -493,686 | -158,123 |
Balance Sheet
| Item | 2017 | 2018 | 2019-03 |
|---|---|---|---|
| Cash and cash equivalents | 58,512 | 958,990 | 824,866 |
| Trade and bills receivables | 19,900 | 6,821 | 5,821 |
| Inventories | 24,668 | 25,203 | 41,869 |
| Total current assets | 232,896 | 1,086,985 | 996,126 |
| Total current liabilities | 1,211,650 | 533,443 | 570,125 |
| Total equity | -75,990 | 1,802,549 | 1,674,829 |
| Equity attributable to owners | -80,074 | 1,802,549 | 1,674,829 |
| Interest-bearing borrowings | 758,428 | 528,018 | 687,913 |
Cash Flow Statement
| Item | 2017 | 2018 | 2019-03 |
|---|---|---|---|
| Net cash from operating activities | -134,288 | -52,179 | -67,575 |
| Net cash from investing activities | -471,662 | -735,375 | -195,295 |
| Net cash from financing activities | 541,380 | 1,679,105 | 145,498 |
| Net increase in cash | -64,570 | 891,551 | -117,372 |
| Depreciation of PP&E | 26,389 | 42,306 | 12,277 |
| Amortisation of intangible assets | 195 | 662 | 305 |
| Purchase of PP&E | -115,387 | -137,070 | -74,051 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 49.45 |
|---|---|
| First Day Open | HK$ 47.45 |
| First Day Change | -0.30% |
| First Day Volume | 6118470.0 |
| First Day Turnover | 295655000.0 |
| Use of Proceeds | 1、約1,238.5百萬港元(或所得款項凈額的40.0%)將用于撥付持續進行的核心產品的臨床試驗、監管備案及注冊;
2、約464.5百萬港元(或所得款項凈額的15.0%)將用于撥付持續進行的其他候選生物類似藥(包括HLX12、HLX11及HLX14)的臨床試驗、監管備案及注冊;
3、約1,083.7百萬港元(或所得款項凈額的35.0%)將用于撥付持續進行的生物創新藥的臨床試驗、監管備案及注冊以及開發免疫腫瘤聯合療法;
4、約309.6百萬港元(或所得款項凈額的10.0%)將分配至營運資金及一般企業用途。 |
Underwriting Syndicate
Joint Sponsors (5)
Overall Coordinators (7)
Joint Bookrunners (15)
中国国际金融香港证券有限公司 CE AEN894
Merrill Lynch (Asia Pacific) Limited CE AAC198
中银国际亚洲有限公司 CE AET863
UBS Securities Hong Kong Limited CE BIN466
招银国际融资有限公司 CE AVM940
Fosun International Securities Limited CE AAF432
Citigroup Global Markets Asia Limited CE AAA137
海通国际证券有限公司 CE AAF806
oOo Securities (HK) Group Limited CE AJH488
BNP PARIBAS SECURITIES (ASIA) LIMITED CE AAF669
ICBC INTERNATIONAL CAPITAL LIMITED CE AQW615
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
农银国际融资有限公司 CE AWL249
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
SBI China Capital Financial Services Limited CE ABD523
Joint Lead Managers (15)
中国国际金融香港证券有限公司 CE AEN894
Merrill Lynch (Asia Pacific) Limited CE AAC198
中银国际亚洲有限公司 CE AET863
UBS Securities Hong Kong Limited CE BIN466
招银国际融资有限公司 CE AVM940
Fosun International Securities Limited CE AAF432
Citigroup Global Markets Asia Limited CE AAA137
海通国际证券有限公司 CE AAF806
oOo Securities (HK) Group Limited CE AJH488
BNP PARIBAS SECURITIES (ASIA) LIMITED CE AAF669
ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
农银国际证券有限公司 CE ACX411
CHINA EVERBRIGHT SECURITIES (HK) LIMITED CE AAW536
SBI China Capital Financial Services Limited CE ABD523
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Al-Rayyan Holding LLC | 704,999,520 HKD | — | 21.97% | — | 6 months | 2020-03-25 |
| 2 | AVICT Global Holdings Limited | 235,208,160 HKD | — | 7.33% | — | 6 months | 2020-03-25 |
| 3 | Henlius Biopharmaceuticals Inc. | 78,402,720 HKD | — | 2.44% | — | 6 months | 2020-03-25 |
| 4 | 浙江舒泰神投资有限公司 | 78,402,720 HKD | — | 2.44% | — | 6 months | 2020-03-25 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 陳啟宇 | — |
| Company Secretary | 郭新軍、梁晶晶 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 復星醫藥透過其全資附屬公司復星醫藥產業發展及復星新藥間接持有約53.76%已發行股份;最終控股股東為郭廣昌先生,其透過FIHL、FHL、復星國際、復星高科技等控制本公司。復星新藥直接持有內資股265,971,569股(佔49.33%)。 |
|---|




